51342 Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the Effisayil 2 and Effisayil ON trials - 02/09/24
Doi : 10.1016/j.jaad.2024.07.192
Akimichi Morita
Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Bruce Strober
Department of Dermatology, Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USA
Tiago Torres
Department of Dermatology, Centro Hospitalar Universitàrio de Santo António, University of Porto, Porto, Portugal
Andreas Pinter
Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany
Angelo V. Marzano
Dermatology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
James G. Krueger
Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA
Mark G. Lebwohl
The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Le texte complet de cet article est disponible en PDF.
| Commercial Support: The study was supported and funded by Boehringer Ingelheim. OPEN Health Communications (London, UK) provided writing, editorial, and formatting support, contracted and funded by Boehringer Ingelheim. |
© 2024
Vol 91 - N° 3S
P. AB46 - septembre 2024 Retour au numéro
Article précédent
- 53552 Flare of Sweet Syndrome After COVID-19 Vaccination
- Daniel Xie, Jeffrey Callen
- 53121 Frankincense: Incensing Dermatologists and Dermatopathologists Managing Melanoma
- Savannah Hodgkin, Marina Ibraheim, Lavonne Meadows, Ashley Elsensohn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?